Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2025-12-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于选举职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an employee representative director to the company's board. It details the changes in the board structure, the election process, and the qualifications of the elected director. There is no financial data, audit information, or report content. The document is about board/management changes, specifically the election of a new board member representing employees. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full report or announcement of a report publication.
2025-12-24 Chinese
北京市天元律师事务所关于新天地药业股份有限公司2025年第三次临时股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2025 third extraordinary shareholders' meeting of a company. It details the legal compliance of the meeting process, the qualifications of attendees, and the voting outcomes on various resolutions. The document is not a financial report, earnings release, or management discussion, but rather a formal legal opinion related to a shareholders' meeting. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official confirmation and legal opinion on the voting results of a shareholders' meeting.
2025-12-24 Chinese
2025年第三次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2025 third extraordinary general meeting of shareholders" of a company. It details the meeting date, attendance, voting results on various proposals including changes to company governance, capital structure, and other corporate governance matters. It includes voting percentages, legal opinions from lawyers, and confirms the legality and validity of the meeting and resolutions. There is no financial data or financial statements presented, nor is this a transcript or presentation. The document is an official announcement of the voting results from a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains detailed voting results, not just a brief notice or report publication announcement. Therefore, the best classification is DVA with high confidence.
2025-12-24 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a pharmaceutical company about receiving an approval notice from the National Medical Products Administration for the listing of a chemical raw material drug. It includes details about the drug, approval number, validity, and impact on the company. The document is short (914 characters) and serves as a formal notification of regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, or shareholder information. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-09 Chinese
非日常经营交易事项决策制度
Governance Information Classification · 95% confidence The document is titled as a decision-making system for non-routine business transactions of a company, detailing internal procedures and approval thresholds for various types of transactions. It is a governance or internal policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or legal proceedings. It is not a report publication announcement or a certification. The content aligns with governance information about company internal rules and decision-making processes for specific transaction types.
2025-12-08 Chinese
投资者关系工作管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Work Management System" for a company, detailing policies, procedures, and organizational structure for managing investor relations. It includes sections on communication principles, target audiences, communication methods, internal coordination, and compliance with laws and regulations. It also contains appendices with forms and commitments related to investor interactions. There are no financial statements, earnings data, audit opinions, or regulatory filings of financial results. The document is a governance and procedural manual related to investor relations management rather than a financial report, announcement, or regulatory filing. Therefore, it best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices, including investor relations policies.
2025-12-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.